CeriBell (NASDAQ:CBLL) VP David Foehr Sells 5,265 Shares

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 5,265 shares of CeriBell stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $16.83, for a total value of $88,609.95. Following the transaction, the vice president owned 19,384 shares in the company, valued at approximately $326,232.72. This trade represents a 21.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

CeriBell Trading Up 3.0%

Shares of CeriBell stock opened at $19.72 on Friday. The business has a fifty day simple moving average of $13.44 and a 200-day simple moving average of $14.41. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The firm has a market cap of $731.53 million, a price-to-earnings ratio of -13.06 and a beta of 1.35. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The firm had revenue of $22.59 million for the quarter, compared to analysts’ expectations of $21.78 million. On average, equities analysts forecast that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of CeriBell in the third quarter valued at $33,000. Tower Research Capital LLC TRC lifted its position in CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after buying an additional 1,801 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of CeriBell by 97.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after buying an additional 1,256 shares during the period. Police & Firemen s Retirement System of New Jersey grew its holdings in shares of CeriBell by 161.0% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after acquiring an additional 3,502 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC acquired a new position in shares of CeriBell in the third quarter worth $135,000.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CBLL. TD Cowen cut their target price on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. Raymond James Financial started coverage on CeriBell in a report on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 target price on the stock. Finally, JPMorgan Chase & Co. reduced their target price on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and a consensus price target of $25.17.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.